PF-06372865, An α2/3/5-Subtype Selective GABA A Partial Positive Allosteric Modulator Has Promising Efficacy In The Photosensitivity Model

被引：0
|
作者：
Gurrell, R. [1 ]
Gorman, D. [1 ]
Whitlock, M. [1 ]
Ogden, A. [2 ]
Reynolds, D. S. [1 ]
DiVentura, B. [3 ]
Abou-Khalil, B. [4 ]
Gelfand, M. [5 ]
Pollard, J. [5 ]
Hogan, R. E. [6 ]
Krauss, G. [7 ]
Sperling, M. [8 ]
Vazquez, B. [9 ]
Wechsler, R. T. [10 ]
Friedman, D. [9 ]
Butt, R. P. [11 ]
French, J. [9 ]
机构：
[1] Pfizer Inc, Cambridge, England
[2] Pfizer Inc, Groton, CT 06340 USA
[3] Epilepsy Study Consortium, Reston, VA USA
[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[5] Univ Penn, Philadelphia, PA 19104 USA
[6] Washington Univ, St Louis, MO 63110 USA
[7] Johns Hopkins Univ Hosp, Baltimore, MD USA
[8] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[9] NYU, Comprehens Epilepsy Ctr, New York, NY USA
[10] Consultants Epilepsy & Neurol PLLC, Boise, ID USA
[11] Pfizer IncI, Cambridge, England
来源：
EPILEPSIA | 2019年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P122
引用
收藏
页码：65 / 65
页数：1
相关论文
共 22 条
  • [1] Design and Identification of a Novel, Functionally Subtype Selective GABAA Positive Allosteric Modulator (PF-06372865)
    Owen, Robert M.
    Blakemore, David
    Cao, Lishuan
    Flanagan, Neil
    Fish, Rebecca
    Gibson, Karl R.
    Gurrell, Rachel
    Huh, Chan Woo
    Kammonen, Juha
    Mortimer-Cassen, Elisabeth
    Nickolls, Sarah A.
    Omoto, Kiyoyuki
    Owen, Dafydd
    Pike, Andy
    Pryde, David C.
    Reynolds, David S.
    Roeloffs, Rosemarie
    Rose, Colin
    Stead, Clara
    Takeuchi, Mifune
    Warmus, Joseph S.
    Watson, Christine
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (12) : 5773 - 5796
  • [2] Safety, Tolerability, and Pharmacokinetics of Multiple Repeated Oral Doses of the α2/3/5-Subtype Selective GABAA-Positive Allosteric Modulator PF-06372865 in Healthy Volunteers
    Gurrell, Rachel
    Whitlock, Mark
    Wei, Hua
    Shen, Zhongzhou
    Ogden, Adam
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (07): : 756 - 764
  • [3] Pronounced antiepileptic activity of the subtype-selective GABAA-positive allosteric modulator PF-06372865 in the GAERS absence epilepsy model
    Duveau, Venceslas
    Buhl, Derek L.
    Evrard, Alexis
    Ruggiero, Celine
    Mande-Niedergang, Betty
    Roucard, Corinne
    Gurrell, Rachel
    CNS NEUROSCIENCE & THERAPEUTICS, 2019, 25 (02) : 255 - 260
  • [4] Analgesic potential of PF-06372865, an α2/α3/α5 subtype-selective GABAA partial agonist, in humans
    van Amerongen, Guido
    Siebenga, Pieter S.
    Gurrell, Rachel
    Dua, Pinky
    Whitlock, Mark
    Gorman, Donal
    Okkerse, Pieter
    Hay, Justin L.
    Butt, Richard P.
    Groeneveld, Geert Jan
    BRITISH JOURNAL OF ANAESTHESIA, 2019, 123 (02) : E194 - E203
  • [5] Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865
    Nickolls, Sarah A.
    Gurrell, Rachel
    van Amerongen, Guido
    Kammonen, Juha
    Cao, Lishuang
    Brown, Adam R.
    Stead, Clara
    Mead, Andy
    Watson, Christine
    Hsu, Cathleen
    Owen, Robert M.
    Pike, Andy
    Fish, Rebecca L.
    Chen, Laigao
    Qiu, Ruolun
    Morris, Evan D.
    Feng, Gang
    Whitlock, Mark
    Gorman, Donal
    van Gerven, Joop
    Reynolds, David S.
    Dua, Pinky
    Butt, Richard P.
    BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (04) : 708 - 725
  • [6] A randomised, placebo-controlled clinical trial with the α2/3/5 subunit selective GABAA positive allosteric modulator PF-06372865 in patients with chronic low back pain
    Gurrell, Rachel
    Dua, Pinky
    Feng, Gang
    Sudworth, Maria
    Whitlock, Mark
    Reynolds, David S.
    Butt, Richard P.
    PAIN, 2018, 159 (09) : 1742 - 1751
  • [7] Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865 (vol 175, pg 708, 2018)
    Nickolls
    BRITISH JOURNAL OF PHARMACOLOGY, 2019, 176 (01) : 127 - 127
  • [8] Efficacy of selective GABA A alpha 5 positive and negative allosteric modulators in the MAM model of schizophrenia
    Grace, A.
    Gill, K.
    Cook, J.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 32 - 32
  • [9] Antinociceptive Effects of a Novel α2/α3-Subtype Selective GABAA Receptor Positive Allosteric Modulator
    Lewter, Lakeisha A.
    Fisher, Janet L.
    Siemian, Justin N.
    Methuku, Kashi Reddy
    Poe, Michael M.
    Cook, James M.
    Li, Jun-Xu
    ACS CHEMICAL NEUROSCIENCE, 2017, 8 (06): : 1305 - 1312
  • [10] A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis
    Benneyworth, Michael A.
    Xiang, Zixiu
    Smith, Randy L.
    Garcia, Efrain E.
    Conn, P. Jeffrey
    Sanders-Bush, Elaine
    MOLECULAR PHARMACOLOGY, 2007, 72 (02) : 477 - 484
123